Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Daiichi Sankyo
With
A patient enrolled in this MAP can continue treatment until any of the following occurs (whichever comes first): * Disease progression. * Unacceptable toxicity. * The benefit-risk no longer favors the individual. * I-DXd becomes commercially available in the US, and reimbursement is approved for the treatment of ES-SCLC. * The patient chooses to discontinue treatment. * Withdrawal of consent. * Pregnancy. * Physician discretion. * Death.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
